Company: BGLC
Filing Date: 2025-11-13
Form Type: 8-K
Source: 0001477932-25-008137
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-13
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01. Entry into a Material Definitive Agreement.

On November 7, 2025, BioNexus Gene Lab Corp. (the “ Company”) entered into an Equity Distribution Agreement (the “ Agreement”) with Maxim Group LLC (the “ Agent”), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the “ Common Stock”), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company’s exclusive sales agent (the “ ATM Program”).

Sales, if any, will be made in transactions deemed to be “at-the-market” offerings as defined in Rule 415 under the Securities Act of 1933, as amended, which may be made directly on The Nasdaq Capital Market or otherwise at prevailing market prices, at prices related to prevailing market prices, or at negotiated prices, as permitted by the Agreement. The Company is not obligated to sell any shares under the Agreement, and the Agent is not required to purchase any shares. No sales will be made pursuant to the Agreement unless and until the Company’s shelf Registration Statement on Form S-3 (File No. 333-291379) is declared effective by the U. S. Securities and Exchange Commission and the Company has filed the applicable prospectus supplement.

The Agreement contains customary representations, warranties, covenants, indemnification and contribution provisions, and customary termination rights. The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.